Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a ...

Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syndax ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is set to release its Q4 2024 earnings on Mar 3, 2025. The consensus estimate for Q4 ...

Citi lowered the firm’s price target on Syndax (SNDX) to $42 from $45 and keeps a Buy rating on the shares post the Q4 report. The firm says ...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $1 per share a year ago. These figures ...

JPMorgan raised the firm’s price target on Syndax (SNDX) to $39 from $35 and keeps an Overweight rating on the shares. The firm updated models ...

SYNDAX PHARMACEUTICALS ($SNDX) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$1.10 per share, missing estimates of -$0.25 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...